Based on these findings, the study authors concluded that CPS ≥10 is a reasonable threshold of tumor PD-L1 expression to define the population of patients with metastatic TNBC who are most likely to benefit from treatment with pembrolizumab in the advanced/metastatic setting. Here, CD274 is linked to neoplasm.